ABBISKO CAYMAN DL-00001 (8ZD) - Total Assets
Based on the latest financial reports, ABBISKO CAYMAN DL-00001 (8ZD) holds total assets worth €2.35 Billion EUR (≈ $2.75 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ABBISKO CAYMAN DL-00001 - Total Assets Trend (2021–2025)
This chart illustrates how ABBISKO CAYMAN DL-00001's total assets have evolved over time, based on quarterly financial data. Also see 8ZD market cap overview for the company's overall valuation and market capitalisation.
ABBISKO CAYMAN DL-00001 - Asset Composition Analysis
Current Asset Composition (December 2025)
ABBISKO CAYMAN DL-00001's total assets of €2.35 Billion consist of 90.4% current assets and 9.6% non-current assets. Review ABBISKO CAYMAN DL-00001 debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 31.8% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.20 Million | 0.2% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how ABBISKO CAYMAN DL-00001's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 8ZD share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ABBISKO CAYMAN DL-00001's current assets represent 90.4% of total assets in 2025, a decrease from 97.2% in 2021.
- Cash Position: Cash and equivalents constituted 31.8% of total assets in 2025, down from 95.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 0.2% of total assets.
ABBISKO CAYMAN DL-00001 Competitors by Total Assets
Key competitors of ABBISKO CAYMAN DL-00001 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
ABBISKO CAYMAN DL-00001 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.98 | 14.92 | 21.75 |
| Quick Ratio | 4.98 | 14.92 | 21.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.70 Billion | €1.88 Billion | €2.09 Billion |
ABBISKO CAYMAN DL-00001 - Advanced Valuation Insights
This section examines the relationship between ABBISKO CAYMAN DL-00001's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.67 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | 11.7% |
| Total Assets | €2.35 Billion |
| Market Capitalization | $653.62 Million USD |
Valuation Analysis
Below Book Valuation: The market values ABBISKO CAYMAN DL-00001's assets below their book value (0.28x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: ABBISKO CAYMAN DL-00001's assets grew by 11.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ABBISKO CAYMAN DL-00001 (2021–2025)
The table below shows the annual total assets of ABBISKO CAYMAN DL-00001 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €2.35 Billion ≈ $2.75 Billion |
+11.68% |
| 2024-12-31 | €2.11 Billion ≈ $2.46 Billion |
-0.39% |
| 2023-12-31 | €2.12 Billion ≈ $2.47 Billion |
-15.03% |
| 2022-12-31 | €2.49 Billion ≈ $2.91 Billion |
-6.22% |
| 2021-12-31 | €2.65 Billion ≈ $3.10 Billion |
-- |
About ABBISKO CAYMAN DL-00001
Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus … Read more